References
- Estey E, Döhner H. Acute myeloid Leukaemia. Lancet 2006; 368: 1894–1907
- Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71–96
- Deschler B, de Witte T, Mertelsmann R, Lübbert M. Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: problems and approaches. Haematologica 2006; 91: 1513–1522
- Menzin J, Lang K, Earle C C, Kerney D, Mallick R. The outcomes and costs of acute myeloid leukemia among the elderly. Arch Intern Med 2002; 162: 1597–1603
- Craig C M, Schiller G J. Acute myeloid leukemia in the elderly: conventional and novel treatment approaches. Blood Rev 2008; 22: 221–234
- List A, Kurtin S, Roe D J, Buresh A, Mahadevan D, Fuchs D, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005; 352: 549–557
- List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006; 355: 1456–1465
- Raza A, Reeves J A, Feldman E J, Dewald G W, Bennett J M, Deeg H J, et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 2008; 111: 86–93
- Vardiman J W, Harris N L, Brunning R D. The world health organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100: 2292–2302
- Löwenberg B, Downing J R, Burnett A. Acute myeloid leukemia. N Engl J Med 1999; 341: 1051–1062
- Grimwade D, Walker H, Harrison G, Oliver F, Chatters S, Harrison C J, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001; 98: 1312–1320
- Stone R M, O'Donnell M R, Sekeres M A. Acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 2004; 98–117
- Kantarjian H M, O'Brien S, Huang X, Garcia-Manero G, Ravandi F, Cortes J, et al. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. Cancer 2007; 109: 1133–1137
- Lancet J E, List A F, Moscinski L C. Treatment of deletion 5q acute myeloid leukemia with lenalidomide. Leukemia 2007; 21: 586–588